Results 111 to 120 of about 4,843 (156)

Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatment. [PDF]

Am J Prev Cardiol
Schwartz GG, Szarek M, Cobbaert CM, Ruhaak LR, Schwertfeger M, Bhatt DL, Bittner VA, Goodman SG, Harrington RA, Stevanovic I, Tavori H, Reijnders E, Romijn F, van Neer NJM, White HD, Jukema JW, Steg PG.   +16 more
europepmc   +1 more source

PROTAC-mediated PCSK9 degradation attenuates atherosclerosis and improves plaque composition via suppression of NF-κB/TNF-α pathway. [PDF]

BMC Med
Wang X, Liu Y, Zhang QP, Zhang MC, Xia MD, Yang P, Chen SL, Guo WM, Liu M, Tang ZH, Fan G, Yang J.   +11 more
europepmc   +1 more source

Management of dyslipidaemia in patients with comorbidities-facing the challenge: heart failure. [PDF]

Eur Heart J Cardiovasc Pharmacother
Drexel H, Frick M, Zirlik A, Niessner A, Huber K, Tamargo J, Dobrev D, Mader A, Agewall S.   +8 more
europepmc   +1 more source

Impact of early initiation of PCSK9I monoclonal antibodies after acute coronary syndrome. [PDF]

Indian Heart J
Goel PK, Kapoor A, Jain KJ, Thachathodiyl R, Reddy V, Guleria V, Bhalla N, Sasidharan S.   +7 more
europepmc   +1 more source

Methodological Concerns Regarding Cardioprotective Effects of PCSK9 Inhibition in Diabetic Rats. [PDF]

Anatol J Cardiol
Afşin A, Uçkaç K, Sarıoğlu G.
europepmc   +1 more source

Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering. [PDF]

Biomolecules
Espadas C, Soto-Catalán M, Romero-Cote M, Kavanagh M, Herrero-Del Real I, Ortega-Hernández A, Lumpuy-Castillo J, Gómez-Garre D, Egido J, Tuñón J, Gómez-Guerrero C, Lorenzo Ó.   +11 more
europepmc   +1 more source

LDL-C target attainment and treatment costs in high-risk and very-high-risk patients with or without bempedoic acid: A Spanish cohort simulation. [PDF]

PLoS One
Cosin-Sales J, Abad-Sazatornil MR, Martín-Conde JA, Alonso Iglesias E, Mostaza Prieto JM.   +4 more
europepmc   +1 more source

Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [PDF]

J Saudi Heart Assoc
AlHabeeb W, Alamri H, Elbadawi H, AlRuthia YS, Alharbi W, Alshammeri O, Tash A, Almoziny S, Kholaif N, Halawani H, AlMahdi F, Yar W, Alhabib KF.   +12 more
europepmc   +1 more source

Alirocumab <i>versus</i> Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis. [PDF]

Curr Cardiol Rev
Cleto AS, Schirlo JM, Machozeki J, Martins CM.   +3 more
europepmc   +1 more source

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]

Eur J Clin Pharmacol
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc   +1 more source